Downstaging of advanced hepatocellular carcinoma followed by liver transplantation using immune checkpoint inhibitors: Where do we stand?

doi:10.4292/wjgpt.v15.i5.97570

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 5

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (1793)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-1) series, Tables (1-2) series.

Item

Count

PDF

HTML

1070

Figures (1-1)

124

Tables (1-2)

134

Sum=1357

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

128

Sum=222

Publishing Process of This Article

Item

Count

Browse

Download

Sum=133

Sep 5, 2024 (publication date) through Dec 21, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Pharmacology and Therapeutics

ISSN

2150-5349

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Gastrointest Pharmacol Ther. Sep 5, 2024; 15(5): 97570
Published online Sep 5, 2024. doi: 10.4292/wjgpt.v15.i5.97570

Open in New Tab Full Size Figure Download Figure

Figure 1 Mechanism of action of immune checkpoint inhibitors for downstaging of hepatocellular carcinoma. TCR: T-Cell Receptor; MHC: Major histocompatibility complex; PD1: Programmed cell death protein 1; PDL1: Programmed death ligand 1; CTLA4: Cytotoxic T-Lymphocyte associated protein 4.

Citation: Pahari H, Peer JA, Tripathi S, Singhvi SK, Dhir U. Downstaging of advanced hepatocellular carcinoma followed by liver transplantation using immune checkpoint inhibitors: Where do we stand? World J Gastrointest Pharmacol Ther 2024; 15(5): 97570
URL: https://www.wjgnet.com/2150-5349/full/v15/i5/97570.htm
DOI: https://dx.doi.org/10.4292/wjgpt.v15.i5.97570